Self-Aggregating Injectable Microcrystals
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Injectable
-
Intended Duration:
- Not Yet Determined
- Development Stage: Discovery & Early Development
- Developer(s)/researcher(s): Massachusetts Institute of Technology
Details
- API: Not Yet Determined - Tested with LNG
- Target: Not Yet Determined
-
Mechanism of Action:
- Not Yet Determined
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Not Potential MPT
- Promising Attributes: Developers suggest in early publications that self-aggregating microcrystals could be used to develop a long-acting product that can be administered through a small-gauge/low-profile needle.
Product Status
Active/Recent Early Development
History
2025: Research team at the Massachusetts Institute of Technology publish results of in vivo and in vitro evaluation of microcrystal-based concept product, suggesting that the use of slower-exchanging solvents and self-aggregating crystals may lead to longer-term drug release without the need for the high-gauge needles required for injection of in-situ forming implants.